Literature DB >> 30860438

Recent clinical trials of immunotherapy in non-small-cell lung cancer.

Stavros Gkolfinopoulos1, Giannis Mountzios2.   

Abstract

Entities:  

Keywords:  atezolizumab; avelumab; checkpoint inhibitors; durvalumab; ipilimumab; nivolumab; non-small-cell lung cancer; pembrolizumab

Mesh：

Substances：

Year:  2019        PMID： 30860438     DOI： 10.2217/imt-2019-0021

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


× No keyword cloud information.
  2 in total

Review 1.  Current Perspectives in Cancer Immunotherapy.

Authors:  Theodoulakis Christofi; Stavroula Baritaki; Luca Falzone; Massimo Libra; Apostolos Zaravinos
Journal:  Cancers (Basel)       Date:  2019-09-30       Impact factor: 6.639

2.  A special prognostic indicator: tumor mutation burden combined with immune infiltrates in lung adenocarcinoma with TP53 mutation.

Authors:  Jing Fu; Yaonan Li; Cuidan Li; Yuyang Tong; Mengyuan Li; Shundong Cang
Journal:  Transl Cancer Res       Date:  2021-09       Impact factor: 1.241
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.